A PHASE 3B MULTICENTER, SINGLE-ARM, OPEN-LABEL SAFETY STUDY OF LY2951742 (GALCANEZUMAB) IN OUTPATIENTS WITH EPISODIC OR CHRONIC CLUSTER HEADACHE
- Registry ID
- I5Q-MC-CGAR
- Source registry
- HEALTH_CANADA
- Status
- Closed
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- ELI LILLY CANADA INC
- Start date
- 2017-09-12
- Completion date
- 2021-01-21
- Last update
- 2016-08-03
Conditions
- CHRONIC CLUSTER HEADACHE
- EPISODIC CLUSTER HEADACHE
Related clinical trials
- A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO CONTROLLED, PARALLEL GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF 2 DOSE REGIMENS (INTRAVENOUS/SUBCUTANEOUS AND SUBCUTANEOUS) OF TEV-48125 VERSUS PLACEBO FOR THE PREVENTION OF CHRONIC CLUSTER HEADACHE
- A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO CONTROLLED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF 2 DOSE REGIMENS (INTRAVENOUS/SUBCUTANEOUS AND SUBCUTANEOUS) OF TEV-48125 VERSUS PLACEBO FOR THE PREVENTION OF EPISODIC CLUSTER HEADACHE
- A MULTICENTER, DOUBLE-BLIND, DOUBLE-DUMMY STUDY TO EXPLORE THE LONG-TERM SAFETY OF TEV-48125 FOR THE PREVENTION OF CLUSTER HEADACHE
- "A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH EPISODIC CLUSTER HEADACHE."
View on source registry